p53-Mediated downregulation of H ferritin promoter

transcriptional efficiency via NF-Y by Faniello, C. et al.
The International Journal of Biochemistry & Cell Biology 40 (2008) 2110–2119
Available online at www.sciencedirect.com
p53-Mediated downregulation of H ferritin promoter
transcriptional efficiency via NF-Y
Maria Concetta Faniello a, Maddalena Di Sanzo a, Barbara Quaresima a,
Francesco Baudi a, Valentina Di Caro b, Giovanni Cuda a, Giovanni Morrone a,
Giannino Del Sal c,d, Giovanni Spinelli b, Salvatore Venuta a, Francesco Costanzo a,∗
a Dipartimento di Medicina Sperimentale e Clinica “G. Salvatore”, Universita` di Catanzaro “Magna Græcia”,
Campus Universitario, Germaneto, 88100 Catanzaro, Italy
b Dipartimento di Biologia Cellulare e dello Sviluppo (Alberto Monroy), Universita` di Palermo, Parco d’Orleans II, 90128 Palermo, Italy
c Laboratorio Nazionale Consorzio Interuniversitario Biotecnologie (LNCIB), Area Science Park, Padriciano 99, 34012 Trieste, Italy
d Dipartimento di Biochimica Bioﬁsica e Chimica delle Macromolecole, Via L: Giorgeri 1, 34023 Trieste, Italy
Received 12 December 2007; received in revised form 7 February 2008; accepted 11 February 2008
Available online 17 February 2008
This paper is dedicated to the memory of one of the authors, Prof. S. Venuta, who recently passed away.
Abstract
The tumor suppressor protein p53 triggers many of the cellular responses to DNA damage by regulating the transcription of a
series of downstream target genes. p53 acts on the promoter of the target genes by interacting with the trimeric transcription factor
NF-Y. H ferritin promoter activity is tightly dependent on a multiprotein complex called Bbf; on this complex NF-Y plays a major
role.
The aim of this work was to study the modulation of H ferritin expression levels by p53. CAT reporter assays indicate that: (i)
p53 overexpression strongly downregulates the transcriptional efficiency driven by an H ferritin promoter construct containing only
the NF-Y recognition sequence and that the phenomenon is reverted by p53 siRNA; (ii) the p53 C-terminal region is sufficient to
elicitate this regulation and that a correct C-terminal acetylation is also required. The H ferritin promoter displays no p53-binding
sites; chromatin immunoprecipitation assays indicate that p53 is recruited on this promoter by NF-Y. The p53–NF-Y interaction
does not alter the NF-Y DNA-binding ability as indicated by electrophoretic mobility shift assay (EMSA) analysis.
These results demonstrate that the gene coding for the H ferritin protein belongs to the family of p53-regulated genes, therefore
adding a new level of complexity to the regulation of the H ferritin transcription and delineate a role for this protein in a series of
actorcellular events triggered by p53 activation.
© 2008 Elsevier Ltd. All rights reserved.
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doi:10.1016/j.biocel.2008.02.0101. IntroductionFerritin, the major iron storage protein, is composed
of 24 subunits of two types, named H and L for heavy and
light, respectively (Arosio, Adelman, & Drysdale, 1978).
Ferritin synthesis is regulated at both transcriptional and
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ranslational levels (Torti & Torti, 2002). The expression
f the two ferritin genes varies among different cell types,
uring cell differentiation and neoplastic transformation
s well as in response to some environmental stimuli
Bevilacqua et al., 1995; Bomford & Munro, 1992).
The human H ferritin promoter spans a length of
50 bp upstream from the transcriptional start, which
ncludes two cis-acting elements (Bevilacqua et al.,
992). The distal element (A box) is a GC box and is
ecognized by the transcription factor Sp1. The proximal
lement (B box) is an inverted CCAAT box and is recog-
ized by a protein complex termed B-box binding factor
Bbf) (Bevilacqua et al., 1992). Bbf is composed of the
rimeric transcription factor NF-Y (Faniello et al., 1999)
hich directly contacts the DNA, the co-activator p300
Bevilacqua, Faniello, Quaresima, et al., 1997; Faniello
t al., 1999) and the histone acetylase pCAF (Bevilacqua,
aniello, Russo, Cimino, & Costanzo, 1998). Recently
e have demonstrated that c-Jun may be recruited to the
romoter by interacting with Bbf, where it stimulates
he transcription efficiency, and that is able to potenti-
te the transcription of the H ferritin promoter without
inding directly to the DNA (Faniello et al., 2002). Bbf
s also able to bind E1A, which acts as a transcriptional
epressor (Bevilacqua, Faniello, Quaresima, et al., 1997).
The NF-Y transcription factor consists of three sub-
nits, NF-YA, B and C, all of which are required for
inding to the CCAAT motif (Maity, Sinha, Ruteshouser,
de Crombrugghe, 1992). NF-Y is ubiquitously
xpressed and activates transcription from various pro-
oters. It has been shown that the DNA-binding activity
f NF-Y changes during different stages of B-cell devel-
pment (Currie, 1998), senescence (Jung et al., 2001;
ang & Chen, 1993) and differentiation (Bevilacqua et
l., 2002; Marziali et al., 1997, 1999). NF-Y is impli-
ated in transcriptional repression of G2-specific genes
fter p53 induction and DNA damage (Ceribelli, Alcalay,
igano, & Mantovani, 2006; Manni et al., 2001; Yun et
l., 1999).
p53 directly activates the expression of genes that con-
ain p53-binding sites within their regulatory regions.
53 also functions as a negative regulator of various
enes, although the promoters of most of these genes do
ot contain a typical binding consensus for this protein
Ginsberg, Mechta, Yaniv, & Oren, 1991). The mecha-
ism by which p53 exerts this inhibition is thought to
nvolve physical interaction either with basal compo-
ents of the transcriptional machinery (Mack, Vartikar,
ipas, & Laimins, 1993; Seto et al., 1992) or with
ther unidentified factors, but its molecular basis remains
argely unclear (Kubicka et al., 1999; Yun et al., 1999).
owever, in at least one case, it has been proposed thathemistry & Cell Biology 40 (2008) 2110–2119 2111
p53 represses transcription through interaction with a
transcription activator rather than the basal transcrip-
tion machinery. To function efficiently as an activator of
gene expression, p53 forms complexes with other tran-
scriptional regulators, including acetyltransferases such
as p300/CBP (Vousden & Lu, 2002).
In this study we have investigated the potential
involvement of p53 in the control of the H ferritin
gene transcription and demonstrate that its expression
represses the H ferritin promoter through inhibition of
the transcriptional effects of NF-Y.
2. Materials and methods
2.1. Northern blot analysis
Total RNA was extracted from HeLa and HCT116
p53−/− cells treated and untreated with doxorubicin
using TRIzol reagent (Invitrogen). Northern blot analy-
sis was performed as previously described (Bevilacqua,
Faniello, Russo, Cimino, & Costanzo, 1994). The
labelled probes were a 528-bp Pst fragment of the H fer-
ritin cDNA (Costanzo et al., 1983) and a 1600-bp Bam HI
fragment from the human glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) cDNA (Arcari, Martinelli, &
Salvatore, 1984).
2.2. Cell culture
HeLa cells, HCT116 w.t. and HCT116 p53−/−, were
cultured as monolayers in Dulbecco’s modified Eagle’s
medium (Life Technologies) supplemented with 10%
(v/v) fetal calf serum (Life Technologies) and 100 units/l
penicillin (Life Technologies). Cells were grown at 37 ◦C
in a 5% CO2 atmosphere. Doxorubicin was added at
0.5g/ml for 20 h (Fig. 1), or 0.5g/ml for 8, 24 and
48 h (Fig. 2).
2.3. DNA transfections and chloramphenicol
acetyltransferase (CAT) assays
The H ferritin promoter/CAT (Bbf TATAA and Bbfmut
TATAA) have been described previously (Bevilacqua,
Faniello, Quaresima, et al., 1997). The plasmid p53
(CMV p53), contains the full-length human w.t. p53
cDNA, p53 siRNA (Gostissa et al., 2004), p53-CT (the
human p53 fragment from aa 294 to 393 was PCR ampli-
fied and cloned downstream of the HA epitope into
pcDNA3), p53 9KR and p53 H175(Gadea, Lapasset,
Gauthier-Rouviere, & Roux, 2002), was a gift from Prof.
G. Del Sal. Transfections were carried out using the
calcium-phosphate technique (Graham & van der Eb,
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Fig. 1. p53 downregulates transcription of the H ferritin promoter.
(A) CAT activity driven by H ferritin promoter/CAT construct (Bbf
TATAA) which contains the inverted CCAAT box and its mutated ver-
sion (Bbfmut/TATAA), transiently transfected in HeLa cells with or
without p53 expression vector and stimulated or not with doxorubicin.
The values are the means ± S.E.M. of three independent transfection
experiments and are expressed as the percentage of the acetylated
Fig. 2. Effect of doxorubicin on H ferritin gene expression. (A) Total
RNA was isolated from HeLa cells treated with doxorubicin at different
times (8, 24 and 48 h) and analyzed by hybridization with a radiola-
belled H ferritin cDNA probe, and with a GAPDH probe as control.
(B) Western blot analysis of H ferritin protein level after the treatment
with doxorubicin. (C) Western blot analysis of p53 and p53 ser-15
after the treatment with doxorubicin. (D) Total RNA was isolated fromform of [14C]chloramphenicol. (B) Western blot analysis with anti-
p53 antibody and anti-tubulin antibody of total extracts from HeLa
cells transfected with or without p53 expression vector and stimulated
or not with doxorubicin.
1973) or the FuGENE-6 reagent (Roche). Variations in
transfection efficiency were corrected by including the
-galactosidase gene as an internal control under the
control of the Rous sarcoma virus (RSV) long terminal
repeat in each experiment. Galactosidase activity was
assayed as described previously (Oliner et al., 1993).
2.4. Western blot analysis
Protein lysates (50g) were separated by 10%
SDS-PAGE, electro-transferred onto a nitrocellulose
membrane and incubated with anti-p53 (sc-263, Santa
Cruz Biotechnology), anti-p53 (ser-15) (9284, Cell
Signaling), anti-H ferritin (sc-25617, Santa Cruz
Biotechnology), or anti-tubulin antibody (sc-7396, Santa
Cruz Biotechnology) followed by incubation with
horseradish peroxidase (HRP)-conjugated goat anti-
mouse or rabbit secondary antibody (sc-2005 and
sc-2030, Santa Cruz Biotechnology). Protein–antibody
complexes were revealed by enhanced chemilumines-
cence with the Santa Cruz Biotechnology ECL system.2.5. Chromatin immunoprecipitation (ChIP)
HeLa cells (107) were treated with 1% formaldehyde
directly into the media for 10 min at room tempera-HCT p53−/− cells treated with doxorubicin at different times (8, 24
and 48 h) and analyzed by hybridization with a radiolabelled H ferritin
cDNA probe, and with a GAPDH probe as control.
ture on a rocking platform. The cells were then washed
and scraped with phosphate-buffered saline and col-
lected by centrifugation at 700 × g for 4 min at 4 ◦C,
resuspended in cell lysis buffer (10 mM Hepes pH 8.0,
85 mM KCl, 0.5% NP-40, protease inhibitor 1g/ml
leupetin, 1g/ml aprotinin, 1 mM PMSF) and incu-
bated on ice for 10 min. The pellet was resuspended in
lysis buffer (50 mM Tris–HCl pH 8.1, 10 mM EDTA,
1% SDS, protease inhibitor) and incubated on ice for
10 min. The DNA was sonicated to give fragments of
approximately 500 bp. Initially, optimum conditions for
sonication were determined by agarose gel analysis
after reversing cross-links and precipitated DNA. The
lysate was diluted 5-fold in ChIP IP buffer (0.01% SDS,
1% Triton-X-100, 1.2 mM EDTA, 16.7 mM Tris pH
8.1, 167 mM NaCl, protease inhibitor 1g/ml leupetin,
1g/ml aprotinin, 1 mM PMSF) and precleared with
100l of protein A beads, which has been pre-adsorbed
of Bioc
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ith sonicated salmon sperm DNA for 90 min at 4 ◦C on
rotary mixer. Beads were collected by centrifugation
t 2000 × g, and chromatin solution was transferred to a
resh microcentrifuge tube. At this stage, the solution
as split into microcentrifuge tubes and immunopre-
ipitated with 5g of NF-YB (sc-7711, Santa Cruz
iotechnology), p53 (sc-263, Santa Cruz Biotechnol-
gy) and p300 antibodies (05-257, Upstate) overnight
t 4 ◦C on a rotating wheel. The immune complexes
ere then captured with 70l of protein A beads, pre-
ared as described above, for 3 h at 4 ◦C on a rotating
heel. The beads were then washed with 1 ml of ChIP
uffer 1 (0.1% SDS, 1% Triton-X-100, 2 mM EDTA,
0 mM Tris pH 8.1, 150 mM NaCl, PMSF), ChIP buffer 2
0.1% SDS, 1% Triton-X-100, 2 mM EDTA, 20 mM Tris
H 8.1, 500 mM NaCl, PMSF), ChIP buffer 3 (0.25 M
iCl, 1% NP-40, 1% deoxycholate, 1 mM EDTA, 10 mM
ris pH 8, PMSF, DTT), and finally twice with TE 1×
nd protease inhibitor 1g/ml leupeptin, 1g/ml apro-
inin, 1 mM PMSF. The protein–DNA complexes were
hen eluted by adding 250l of ChIP elution buffer (1%
DS, 0.1 M NaHCO3) to the beads and vortexing before
ncubating at room temperature for 15 min. After cen-
rifugation, the eluate was transferred to a fresh tube
nd the elution process was repeated with the beads.
he eluates were then combined, the cross-links were
eversed by adding 1 mg/ml RNAse, 5 mM NaCl and
ncubating for 4 h at 65 ◦C. After centrifugation, the pel-
et was resuspended in 100l of H2O and 2l of 0.5 mM
DTA, 4l of 1 M Tris pH 6.5 and 1l of proteinase K
20 mg/ml) were added and incubated for 1 h at 45 ◦C.
he DNA was then recovered by phenol–chloroform
xtraction.
.6. PCR
PCRs were carried out by using Taq DNA polymerase
Promega), 2l of template DNA and 10 pmol of each
rimer. An input DNA sample was also used as a control
or the PCRs. The amplifications were performed with
he following primers:
ferritin promoter forward 5′ CGCTGTCCCAGAGGCAGTC 3′
ferritin promoter reverse 5′ TGGTCTCTTATAGCCGCGTCGG
3′
SH2 promoter forward 5′ GCTGAGTAAACACAGAAA 3′
SH2 promoter reverse 5′ CTCCTGGTTGAAGAAAAT 3′.7. Electrophoretic mobility shift assay (EMSA)
Nuclear extracts were prepared from HeLa cells as
escribed previously (Bevilacqua et al., 1994). The
ligonucleotides used for EMSA werehemistry & Cell Biology 40 (2008) 2110–2119 2113
forward 5′ CGGCGCTGATTGGCCGGGGCGGGC
3′;
reverse 5′ GCCCGCCCCGGCCAATCAGCGCCG 3′.
EMSA and competition assays were performed as
described previously (Bevilacqua et al., 1995).
2.8. RT-PCR
Total RNA was prepared from HCT116 wild type
and p53−/− cells. A total of 1g of RNA was used
to generate cDNAs with random primers by SuperScript
II reverse transcriptase (Invitrogen). PCR amplification
was carried out under standard condition with Taq DNA
polymerase (Promega). Primer sequences used for H
ferritin gene were
forward 5′ CATCAACCGCCAGATCAAC 3′;
reverse 5′ GATGGCTTTCACCTGCTCAT 3′.
For GAPDH, the primers used were
forward 5′ TGATGACATCAAGAAGGTGGTGAAG
3′;
reverse 5′ TCCTTGGAGGCCATGTGGGCCAT 3′.
3. Results
3.1. p53 overexpression reduces transcription
driven by H ferritin promoter
The human H ferritin promoter contains a CCAAT
box recognized by the transcription factor NF-Y
(Faniello et al., 1999). NF-Y was shown to be
required for the p53-mediated inhibition of several genes
(Imbriano et al., 2005; Joshi, Wu, Reed, & Suttle, 2003;
Zhou, Mehta, Choi, Scolavino, & Zhang, 2003). To
examine the effect of p53 on the H ferritin transcription,
we transiently transfected HeLa cells with a construct
bearing only the CCAAT sequence fused to the TATAA
box of the H promoter gene (Bbf/TATAA) (Bevilacqua,
Faniello, Quaresima, et al., 1997) upstream of the CAT
reporter gene in the presence or absence of the p53
expression vector. As an internal control to monitor
transfection efficiency, the plasmid RSV -GAL carry-
ing the -galactosidase gene under the control of the
RSV promoter was co-transfected. The results, shown
in Fig. 1A, indicate that the transcription of the CAT
gene driven by the H ferritin promoter is markedly inhib-
ited by co-expression of p53 (lane 2). Since previous
studies have shown that doxorubicin treatment stimu-
of Bioc2114 M.C. Faniello et al. / The International Journal
lates the nuclear accumulation and phosphorylation of
p53, we also tested the activity of the H ferritin pro-
moter in response to doxorubicin and found that activity
of the construct was inhibited by doxorubicin treatment
(Fig. 1A, lane 3). As a control, a construct carrying
the mutated version of the NF-Y site (Bbfmut/TATAA)
was co-transfected. As expected, this construct showed
low basal activity and did not respond to doxorubicin
treatment (Fig. 1A, lane 6) and to p53 co-transfection
(Fig. 1A, lane 5). The expression of exogenous p53
(Fig. 1B, lanes 2 and 5) and the induction of the expres-
sion of endogenous p53 in response to doxorubicin
(Fig. 1B, lanes 3 and 6) were confirmed by Western blot
analysis.
Next, we examined by Northern blot analysis the
H ferritin mRNA levels in HeLa cells treated with
doxorubicin at different times. As shown in Fig. 2A,
lower amounts of transcripts were detected in HeLa
cells treated with the drug. This effect was present
after 8 h exposure and maintained throughout the exper-
iment, whereas no changes were detected in the levels
of GAPDH mRNA measured as an internal control. Pro-
tein expression levels were evaluated by Western blot
Fig. 3. Transcriptional activity of the H ferritin gene promoter in HCT116
activity driven by H ferritin promoter/CAT construct (Bbf TATAA) transientl
p53 expression vector, with or without siRNA p53 and with or without pcDNA3
experiments and are expressed as the percentage of [14C]chloramphenicol a
HCT116 wild type and p53−/− cells transfected with or without p53 express
Western blot analysis with anti-p53 and anti-anti-tubulin antibodies of total e
without p53 expression vector, with or without p53 siRNA and with or withohemistry & Cell Biology 40 (2008) 2110–2119
analysis using anti-H ferritin antibody. As expected, dox-
orubicin significantly decreased the H ferritin levels, but
not those of tubulin used as an internal control (Fig. 2B).
Concomitantly with the decrease in H ferritin mRNA and
protein expression levels, doxorubicin treatment induced
accumulation of p53 as well as phosphorylation of p53
at ser-15 (Fig. 2C). To validate the p53-dependency of H
ferritin downregulation upon doxorubicin treatment, H
ferritin mRNA was measured in HCT p53−/− (Fig. 2D).
To confirm the role of p53 in the repression of the
H ferritin gene, the H ferritin promoter (Bbf TATAA)
was transfected in HCT116 cells, as well as in their
p53−/− mutant counterpart. As shown in Fig. 3A, the
activity of the H ferritin promoter was significantly
higher in HCT116 p53−/− cells (Fig. 3A, lane 4)
compared with wild type cells (Fig. 3A, lane 1). Trans-
fection of wild type HCT116 with siRNA specific to
the p53 (Fig. 3A, lane 3) resulted in increased activity
of the Bbf TATAA promoter, similar to that observed
in p53−/−cells (Fig. 3A, lane 4), whereas transfection
of HCT116 p53−/− cells with a p53 expression vector
caused a significant decrease in the activity of the pro-
moter (Fig. 3A, lane 6). Transfection of both wild type
wild type and p53−/− cells and effect of p53 modulation. (A) CAT
y transfected in HCT116 wild type and p53−/− cells with or without
. The values are the means ± S.E.M. of three independent transfection
cetylation. (B) RT-PCR of the H ferritin mRNA of total RNA from
ion vector, with or without siRNA and with or without pcDNA3. (C)
xtracts from HCT116 wild type and p53−/− cells transfected with or
ut pcDNA3.
of Biochemistry & Cell Biology 40 (2008) 2110–2119 2115
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Fig. 5. The C-terminal region of p53 is necessary for the inhibition of
the H ferritin promoter. CAT activity driven by H ferritin promoter/CAT
construct (Bbf TATAA) transiently transfected in HeLa cells with p53,M.C. Faniello et al. / The International Journal
CT116 and HCT116 p53−/−with the empty vector did
ot show significant changes in CAT activity (Fig. 3A,
anes 2 and 5, respectively). These results were sub-
tantiated by the analysis of the ferritin mRNA levels
ssayed by RT-PCR (Fig. 3B). The expression of p53
n the different samples was monitored by Western blot
Fig. 3C).
.2. p53 is a member of the H ferritin promoter
inding complex
To test whether p53 interacts in vivo with the tran-
criptional factor NF-Y on the H ferritin promoter,
hereby modulating the transcription of this gene, we
arried out a ChIP assay with antibodies to NF-Y, p53
nd p300. Chromatin from HeLa cells was immuno-
recipitated with anti-NF-YB, anti-p53 and anti-p300
ntibodies, with non-immune antisera and the immuno-
recipitated DNA fragments were analyzed by PCR
sing primers designed for the H ferritin promoter.
Amplified DNA fragments were detected in anti-NF-
B (-YB), in anti-p53 (-p53) and in anti-p300 (-
300) immunoprecipitates but not in the control (-Ctl)
Fig. 4A). As a further control, we used primers for the
romoter of the MSH2 gene, which does not contain sites
or NF-Y and p53. As expected, no PCR product was
etected using these primers (Fig. 4B).
.3. Inhibition by p53 is dependent on NF-Y
nteractionIt has been shown that the carboxyl-terminal region of
53 is required for NF-Y interactions and the acetylation
f the lysine residues within this domain is impor-
ig. 4. ChIP analysis of NF-Y p53 and p300 on the H ferritin pro-
oter. Chromatin immunoprecipitations were performed with HeLa
ells using the p53, NF-Y, p300 antibodies and non-immune antis-
ra. Immunoprecipitated DNA was amplified by PCR using primers
esigned for the H ferritin promoter (A) and MSH2 promoter as control
B).C-terminal p53 (p53-CT), p53 9KR and with p53 H175. The values
are the means ± S.E.M. of three independent transfection experiments
and are expressed as percentage of [14C]chloramphenicol acetylation.
tant for p53-mediated repression of CCAAT-containing
promoters (Imbriano et al., 2005). We therefore asked
whether the C-terminal region of p53 is necessary for
the downregulation of the H ferritin promoter. To this
end, HeLa cells were co-transfected with an expression
plasmid (p53-CT) carrying the p53 C-terminal domain
and with the H ferritin promoter–CAT reporter plas-
mid. As shown in Fig. 5, the expression of the p53
C-terminal portion reduced the H ferritin promoter basal
activity. Co-transfection with a p53 mutant (p53-9KR),
in which all lysine in the C-terminal are replaced with
arginine, failed to repress the H ferritin promoter. A
similar behaviour was observed upon co-transfection of
the p53-H175, in which the mutation mapping to the
DNA-binding domain of p53 results in the loss of the
sequence-specific DNA-binding activity, therefore act-
ing as dominant-negative mutant of the endogenous p53.
3.4. Binding of NF-Y transcription factor to the H
ferritin promoter is not inhibited by expression of
p53
The ChIP experiments suggest that p53 is bound in
vivo to NF-Y on the H ferritin promoter. To analyze
the role of p53 in the binding of NF-Y to the H fer-
ritin promoter, EMSAs were performed. A synthetic
oligonucleotide corresponding to the NF-Y recognition
sequence on the H ferritin promoter was incubated with
nuclear extracts from HeLa cells either mock-transfected
(Fig. 6A, lane 1) or transfected with the p53 expression
vector (lane 2). p53 overexpression did not affect the
2116 M.C. Faniello et al. / The International Journal of Biochemistry & Cell Biology 40 (2008) 2110–2119
Fig. 6. p53 does not affect the binding of NF-Y to the H ferritin promoter. (A) The terminally labelled oligonucleotide corresponding to the NF-Y
recognition sequence on the H ferritin promoter was incubated with 4g of nuclear extracts from HeLa cells mock-transfected (lane 1) and HeLa
cells transfected with p53 expression vector (lane 2). Lane 3 as lane 2 plus 100-fold molar excess of unlabelled oligonucleotide, lane 4 as lane 2
rn blot
sion ve
xpressioplus 100-fold molar excess of unrelated competitor oligo. (B) Weste
mock-transfected (lane 1) and HeLa cells transfected with p53 expres
cells mock-transfected (lane 1) and HeLa cells transfected with p53 e
binding of NF-Y to the H ferritin promoter (Fig. 6A,
lane 2). Western blot analysis shows that p53 is over-
expressed in p53-transfected HeLa cells (Fig. 6B, lane
2). Coomassie and silver staining confirmed that equal
amounts of proteins were loaded (Fig. 6C).
4. Discussion
The expression of human ferritin genes is regulated
at transcriptional (Bevilacqua et al., 1994; Bevilacqua,
Faniello, Cimino, et al., 1997), post-transcriptional and
translational level (Klausner, Rouault, & Harford, 1993).
The multiplicity of the mechanisms governing the fer-
ritin gene expression, together with the number of extra
and intracellular stimuli, may explain the variety of
isoferritins exploited by a single cell under different
physiological and pathological conditions. The tran-
scription driven by the H ferritin promoter is tightly
dependent on the presence of the trimeric factor NF-Y
(Faniello et al., 1999) on the inverted CCAAT box (B-
box). NF-Y binds the central domain of the co-activator
molecule p300 (Faniello et al., 1999) which, in turn, acts
as a molecular “anchor” recruiting on the H ferritin gene
promoter the oncoprotein E1A, a ferritin transcriptional
repressor (Bevilacqua, Faniello, Quaresima, et al., 1997),
or c-Jun, which acts as an activator (Faniello et al., 2002).analysis with anti-p53 antibody of nuclear extracts from HeLa cells
ctor (lane 2). (C) Coomassie blue-stained nuclear extracts from HeLa
n vector (lane 2).
p53 is known to directly activate a subset of genes
important for cell cycle arrest (el-Deiry et al., 1993;
Kastan et al., 1992) or apoptosis (Nakano & Vousden,
2001; Okamura et al., 2001) by binding to specific
nucleotide sequences located within the promoter region
or the first intron of these genes (el-Deiry, Kern,
Pietenpol, Kinzler, & Vogelstein, 1992). In addition, p53
can function as a negative regulator of various genes,
although the promoters of most of these genes do not
contain a typical consensus binding site for this protein,
therefore suggesting that the interaction of p53 with other
transcription factors is essential for this effect (Mack et
al., 1993; Yun et al., 1999). The transcription factor NF-Y
has been shown to play an important role in regulat-
ing expression and mediating p53-depending repression
of several cell cycle-regulated genes, such as cyclin A,
cyclin B, cyclin B2, cdc2 and cdc25C (Bolognese et al.,
1999; Manni et al., 2001; Yun et al., 1999). Interestingly,
p53 can bind promoters lacking consensus p53-binding
sites, but harbouring at least two CCAAT boxes.
In this study, we investigated a mechanism by which
p53 negatively regulates transcription of the H fer-
ritin gene in the presence of a single active CCAAT
box. We demonstrated that p53, when overexpressed or
activated by doxorubicin, strongly inhibits the expres-
sion of a reporter gene driven by the H ferritin gene
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romoter. The inhibition of CAT expression was accom-
anied by repression of the H ferritin endogenous gene,
s demonstrated by the strong decrease in H ferritin
RNA and protein levels in response to doxorubicin.
ur findings are in apparent contrast with a recent
tudy by Corna, Galy, Hentze, and Cairo (2006) in
hich the treatment with doxorubicin increases mRNA
ferritin levels in rat heart. Preliminary unpublished
ata from our group conducted on rat cardiomyocytes
onfirm this finding. We cannot provide a clear expla-
ation for this discrepancy, but we hypothesize that a
issue-specific response might be taken into account.
oreover, it must be noticed that the concentrations of
oxorubicin used in our experimental setting were dif-
erent from those used by Corna et al. (2006) (1M vs.
–10M). Also, even though rat and human H ferritin
romoters are highly homologous, the iron responsive
lement (IRE), whose binding to iron responsive proteins
IRPs) is impaired by doxorubicin, share only a 40%
f homology, and therefore this could account for the
iverse behaviour between cardiomyocytes and HeLa
ells.
Notably, p53 modulation of H ferritin expression is
emarkably mimicked by two homologues, namely p63
nd p73, that, albeit linked to different upstream path-
ays, nevertheless seem to share a regulatory effect on a
ommon set of genes (Levrero et al., 2000) (Faniello et
l., manuscript in preparation). Transfection of synthetic
hort interfering RNA (p53 siRNA) reversed the tran-
criptional block and restored reporter gene expression
s well as ferritin mRNA levels.
Moreover, we have demonstrated by ChIP analysis
hat NF-Y and p53 can bind to the H ferritin pro-
oter containing a single CCAAT site, although this
romoter is lacking canonical p53-binding sequences.
lectrophoresis mobility shift experiments showed that
53 does not reduce the binding of NF-Y to the H ferritin
romoter, suggesting the possibility that p53 interferes
ith NF-Y recruitment of co-activators and/or general
ranscription factors. This hypothesis is supported by the
vidence that p53 and NF-Y bind to overlapping domains
f the p300 co-activator and both p53 and NF-Y bind to
ATA-binding protein (Bellorini et al., 1997).
p53 post-translational modifications, in particular
cetylation of the lysine residues at the C-terminus,
re known to be essential for the activation of the pro-
ein (Joshi et al., 2003). Our data indicate that, when
ysines are mutated into arginines, p53 fails to repress
he transcriptional activity of the H ferritin promoter.
urthermore, co-transfection of a cDNA encoding the
-terminal portion of p53, required for NF-Y interac-
ion (Imbriano et al., 2005), strongly reduced the ferritinhemistry & Cell Biology 40 (2008) 2110–2119 2117
promoter basal activity, indicating that the carboxyl-
terminal portion of p53 is sufficient to inhibit the
transcription of the H ferritin gene.
Our findings underscore the potential role of H fer-
ritin in mediating p53 effects on cell cycle, DNA repair
and apoptosis in response to a variety of environmental
stress. Among them, oxidative stress, both endogenously
and exogenously produced, is a major threat to organ-
ism survival. Among the multiple targets triggered by
this injury, including transmembrane receptors and intra-
cellular kinases, there is the H ferritin gene. Strong
experimental evidence indicates that the H subunit plays
an important role as a protectant against oxidative stress
(Arosio & Levi, 2002). Hydrogen peroxide-induced cell
toxicity is significantly reduced in cells overexpressing
H ferritin (Cozzi et al., 2000). The molecular mecha-
nisms underlying the protective effect of ferritin against
oxidants are still under investigation. Ferritin is the major
intracellular iron storage protein and can act in the free
iron-reactive oxygen species (ROS) system either as
source of iron, or as a cytoprotective agent towards ROS,
by chelating the free iron in a non-toxic, rapidly available
form, thanks also to the iron-oxidative activity of the H-
chain (Tacchini, Recalcati, Bernelli-Zazzera, & Cairo,
1997). The increase in ferritin expression produces a
reduction of the labile iron pool, as well as the degener-
ative and pro-apoptotic effects ROS-mediated (Epsztejn
et al., 1999).
We propose that the inhibition of H ferritin expres-
sion by p53, which reduces the ROS-scavenging activity
of this protein, might enhance the pro-apoptotic effects
of p53, therefore contributing to the tumor suppressor
activity of this major cell cycle regulator. Moreover, the
mechanism by which H ferritin expression is repressed
by p53, i.e. the binding to a single CCAAT site via NF-
Y, with the contribution of p300 and pCAF, widens the
scenario of physiopathological cell conditions to which
ferritin is able to respond.
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